MedTrace Logo

Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea

NCT01137136 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2014-04-21

No results posted yet for this study

Summary

Aromatase(CYP19)inhibitor is one of the major antihormonal drug for breast cancer in postmenopausal women. The variation of CYP19 may affect the effect of aromatase inhibitor. However, the incidence of variation of CYP19 in Korea has not known. Therefore, the investigators want to know the incidence of variation of CYP19 and to assess the effect of these variations of CYP19 to aromatase inhibitor users.

Conditions

  • Polymorphism
  • CYP19
  • Aromatase Inhibitor

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Seok Jin Nam, M.D., Ph.D. · Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Surgery

Eligibility

Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2014-12-31
Completion
2015-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01137136 on ClinicalTrials.gov